Core Viewpoint - The Schall Law Firm is investigating Allarity Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Allarity issued false or misleading statements and failed to disclose relevant information to investors [2]. - Allarity filed a Form 8-K with the SEC on July 22, 2024, indicating that it received a "Wells Notice" from the SEC regarding its disclosures related to meetings with the FDA concerning its New Drug Application for Dovitinib [2]. - The Wells Notice also indicated that three former officers of Allarity received similar notices from the SEC, and the SEC staff has made a preliminary determination to recommend enforcement action against the Company for alleged violations of federal securities laws [2].
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm